Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Depreciation & Amortization (CF): 2016-2024

Historic Depreciation & Amortization (CF) for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Dec 2024 value amounting to $2.8 million.

  • Crinetics Pharmaceuticals' Depreciation & Amortization (CF) rose 31.43% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year increase of 63.08%. This contributed to the annual value of $2.8 million for FY2024, which is 153.64% up from last year.
  • According to the latest figures from FY2024, Crinetics Pharmaceuticals' Depreciation & Amortization (CF) is $2.8 million, which was up 153.64% from $1.1 million recorded in FY2023.
  • In the past 5 years, Crinetics Pharmaceuticals' Depreciation & Amortization (CF) ranged from a high of $2.8 million in FY2024 and a low of $922,000 during FY2021.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $1.1 million (2023), whereas its average is $1.6 million.
  • In the last 5 years, Crinetics Pharmaceuticals' Depreciation & Amortization (CF) declined by 2.74% in 2021 and then surged by 153.64% in 2024.
  • Yearly analysis of 5 years shows Crinetics Pharmaceuticals' Depreciation & Amortization (CF) stood at $948,000 in 2020, then fell by 2.74% to $922,000 in 2021, then increased by 6.62% to $983,000 in 2022, then grew by 11.70% to $1.1 million in 2023, then soared by 153.64% to $2.8 million in 2024.